MTEX vs NAGE
Mannatech Inc. and Niagen Bioscience, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MTEX | NAGE |
|---|---|---|
| Revenue | $108.0M | $129.4M |
| Net income | $-15.2M | $17.4M |
| Gross margin | 74.9% | 64.3% |
| Net margin | −14.1% | 13.4% |
| Return on equity | −897.3% | 28.3% |
| Diluted EPS | −$8.00 | $0.20 |
| Dividend / share | $0.20 | — |
| Payout ratio | 0.0% | — |
| Free cash flow | $-4.3M | $-21.2M |
| Equity | $-5.2M | $76.5M |
| Net debt / equity | −0.97× | — |
| Current ratio | 1.10× | 4.86× |
| Revenue CAGR 5y | −6.5% | 16.9% |
| Profit CAGR 5y | — | — |
NAGE bills 1.2× the revenue of MTEX, and MTEX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | MTEX | NAGE |
|---|---|---|
| FY2025 | $108.0M | $129.4M |
| FY2024 | $117.9M | $99.6M |
| FY2023 | $132.0M | $83.6M |
| FY2022 | $137.2M | $72.0M |
| FY2021 | $159.8M | $67.4M |
| FY2020 | $151.4M | $59.3M |
| FY2019 | $157.7M | $46.3M |
| FY2018 | $173.6M | $31.6M |
| FY2017 | $176.7M | $21.2M |
| FY2016 | $180.3M | $21.7M |
Net income by year
Bottom line
| Fiscal year | MTEX | NAGE |
|---|---|---|
| FY2025 | $-15.2M | $17.4M |
| FY2024 | $2.5M | $8.6M |
| FY2023 | $-2.2M | $-4.9M |
| FY2022 | $-4.5M | $-16.5M |
| FY2021 | $9.8M | $-27.1M |
| FY2020 | $6.3M | $-19.9M |
| FY2019 | $3.3M | $-32.1M |
| FY2018 | $-3.9M | $-33.3M |
| FY2017 | $-1.8M | $-11.4M |
| FY2016 | $-586,000 | $-2.9M |
Advertisement
AdSense · Rectangle 336×280
More in this industry